|1.||Mishra, Ram K: 2 articles (04/2013 - 01/2003)|
|2.||Yu, Chuanhui: 2 articles (01/2010 - 07/2009)|
|3.||Kastin, Abba J: 2 articles (01/2010 - 07/2009)|
|4.||Pan, Weihong: 2 articles (01/2010 - 07/2009)|
|5.||Hsuchou, Hung: 2 articles (01/2010 - 07/2009)|
|6.||Hoti, S L: 1 article (02/2015)|
|7.||Sharma, Rohit: 1 article (02/2015)|
|8.||Chauhan, Nikhil: 1 article (02/2015)|
|9.||Johnson, Rodney L: 1 article (04/2013)|
|10.||Tan, Mattea L: 1 article (04/2013)|
|1.||Parkinson Disease (Parkinson's Disease)
01/01/2010 - "MIF-1 (Pro-Leu-Gly-NH(2)) is a tripeptide for which the therapeutic potential in Parkinson's disease and depression has been indicated by many studies. "
01/01/2010 - "The cellular activation in specific brain regions illustrates the biochemical and neuroanatomical basis underlying the therapeutic effect of MIF-1 in Parkinson's disease and depression."
07/01/2009 - "MIF-1 (Pro-Leu-Gly-NH(2)) has potent therapeutic effects in depression and Parkinson's disease, but its CNS sites of production are not yet clear. "
01/01/2003 - "Central dopaminergic systems are implicated in schizophrenia and Parkinson's disease, and are known to be modulated by the endogenous tripeptide Pro-Leu-Gly-NH(2) (PLG or MIF-1, melanocyte-stimulating hormone release inhibiting factor-1). "
04/22/1999 - "The effects of Pro-Leu-Gly-NH2 analogues 3a-3d and 4a-4d on enhancing rotational behavior induced by apomorphine in the 6-hydroxydopamine-lesioned animal models of Parkinson's disease were studied. "
|2.||Movement Disorders (Movement Disorder)
04/01/1977 - "Melanocyte-stimulating-hormone release-inhibiting factor-I and tardive dyskinesia."
05/01/1990 - "It is, therefore, possible that the effects of MIF-1 in movement disorders are associated with increased melatonin secretion. "
05/01/1990 - "MIF-induced augmentation of melatonin functions: possible relevance to mechanisms of action of MIF-1 in movement disorders."
07/01/1980 - "MSH and MIF-I in animal models of tardive dyskinesia."
05/01/1990 - "MIF-1 has been reported to potentiate the melanocyte-lightening effect of melatonin in rats and its effects in patients with Parkinson's disease and Tardive dyskinesia are associated with marked mood elevation. "
05/01/1990 - "There is evidence to suggest that MIF-1 increases nigro-striatal dopaminergic activity, but its ability to improve symptoms in patients with Parkinson's disease, levodopa-related dyskinesias and Tardive dyskinesia cannot be explained solely on the basis of the drug's effect on striatal dopaminergic neurons. "
05/01/1990 - "MIF-1, a synthetic tripeptide with MSH-release inhibitory properties, has been reported to improve symptoms of Parkinson's disease, attenuate levodopa-related dyskinesias and diminish the dyskinetic movements of Tardive dyskinesia. "
08/01/1981 - "Effects of naltrexone and prolyl-leucyl-glycinamide on drug-induced tremor and rigidity in the rat."
06/01/1977 - "Pro-Leu-Gly-NH2 (MIF) inhibits the tremor induced by oxotremorine. "
01/01/1976 - "Peptides related to melanostatin (Pro-Leu-Gly-NH2) as inhibitors of oxotremorine-induced tremor."
08/15/1974 - "Studies on the inhibition of oxotremorine induced tremor by a melanocyte-stimulating hormone release-inhibiting factor, thyrotropin releasing hormone and related peptides."
|1.||Melanocyte-Stimulating Hormones (MSH)
|3.||1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
|4.||Levodopa (L Dopa)
|9.||Antipsychotic Agents (Antipsychotics)
|10.||Thyrotropin-Releasing Hormone (Protirelin)